# Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer

> **NCT03298763** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University College, London** · enrollment: 46 (estimated)

## Conditions studied

- Adenocarcinoma of Lung

## Interventions

- **GENETIC:** MSCTRAIL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03298763
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-05
- **Primary completion:** 2023-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2021-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03298763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03298763, "Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03298763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*